Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Workplace Health & Safety|July 24, 2025
Occupational Health Perspectives on Motherhood and Work: A Phenomenological Study in OmanGowda Parameshwara Prashanth, Amna Ibrahim Al Farsi, Mariya Sulaiman Al Zakwani
International Journal of Surgery Case Reports|November 20, 2019
A Neglected Case of Multifocal Liposarcoma Presented in Five Different Sites in a Syrian Woman: A case reportIeman Alawad, Ahmad Al-Haj, Ahmad Ghazal, et al.
Frontiers in Psychology|February 3, 2025
A cross-sectional study to explore the relationship between the technology acceptance model and burnout and depression among pharmacists working with a pharmacy robotic dispensing systemAmna Ibrahim Alshamsi, Mariam AlHarthi, Hessa AbdulQader, et al.
BMC Neurology|September 18, 2023
Retinal functional and structural changes in patients with Parkinson's diseaseRehab Elanwar, Hatem Al Masry, Amna Ibrahim, et al.
International Journal of Technology Assessment in Health Care|December 18, 2024
Road toward institutionalizing health technology assessment in the Emirate of Abu Dhabi: The role of evidence-informed deliberative processesLeon Bijlmakers, Pinar Egeli, Amna Ibrahim Al Saeedi, et al.
The Oncologist|February 3, 2004
FDA drug approval summaries: oxaliplatinAmna Ibrahim, Steven Hirschfeld, Martin H Cohen, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 19, 2016
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder CancerJonathan Jarow, V Ellen Maher, Shenghui Tang, et al.
The Oncologist|October 14, 2008
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2Qin Ryan, Amna Ibrahim, Martin H Cohen, et al.
The Oncologist|February 25, 2017
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker AnalysisJames Xunhai Xu, V Ellen Maher, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2014
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancerLaleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, et al.
Pageof 6